Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Hochster

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Investigational New Drugs|September 8, 2018
Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancerLaura W Goff, Nilofer S Azad, Stacey Stein, et al.
Investigational New Drugs|October 19, 2018
Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancerLaura W Goff, Nilofer S Azad, Stacey Stein, et al.
The Oncologist|February 18, 2017
A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal CancerJohanna C Bendell, Howard Hochster, Lowell L Hart, et al.
Investigational New Drugs|July 1, 2009
Phase II study of darinaparsin in patients with advanced hepatocellular carcinomaJennifer Wu, Charles Henderson, Lynn Feun, et al.
The New England Journal of Medicine|March 14, 2008
VEGF inhibition and renal thrombotic microangiopathyVera Eremina, J Ashley Jefferson, Jolanta Kowalewska, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2020
Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancerRichard D Kim, Shannon McDonough, Anthony B El-Khoueiry, et al.
JCO Precision Oncology|December 3, 2024
Evolution of Rapid Clonal Dynamics and Non-Cross-Resistance in Response to Alternating Targeted Therapy and Chemotherapy in BRAF-V600E-Mutant Colon CancerSrilatha Simhadri, Jillian N Carrick, Susan Murphy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2026
NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal CanalVan K Morris, Kristen K Ciombor, Lianchun Xiao, et al.
Cancers|February 13, 2026
Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001Elena Gabriela Chiorean, Sheela R Damle, David B Zhen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2016
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized TrialsQian Shi, Christopher R Flowers, Wolfgang Hiddemann, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Investigational New Drugs|September 8, 2018
Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancerLaura W Goff, Nilofer S Azad, Stacey Stein, et al.
Investigational New Drugs|October 19, 2018
Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancerLaura W Goff, Nilofer S Azad, Stacey Stein, et al.
The Oncologist|February 18, 2017
A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal CancerJohanna C Bendell, Howard Hochster, Lowell L Hart, et al.
Investigational New Drugs|July 1, 2009
Phase II study of darinaparsin in patients with advanced hepatocellular carcinomaJennifer Wu, Charles Henderson, Lynn Feun, et al.
The New England Journal of Medicine|March 14, 2008
VEGF inhibition and renal thrombotic microangiopathyVera Eremina, J Ashley Jefferson, Jolanta Kowalewska, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2020
Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancerRichard D Kim, Shannon McDonough, Anthony B El-Khoueiry, et al.
JCO Precision Oncology|December 3, 2024
Evolution of Rapid Clonal Dynamics and Non-Cross-Resistance in Response to Alternating Targeted Therapy and Chemotherapy in BRAF-V600E-Mutant Colon CancerSrilatha Simhadri, Jillian N Carrick, Susan Murphy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2026
NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal CanalVan K Morris, Kristen K Ciombor, Lianchun Xiao, et al.
Cancers|February 13, 2026
Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001Elena Gabriela Chiorean, Sheela R Damle, David B Zhen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2016
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized TrialsQian Shi, Christopher R Flowers, Wolfgang Hiddemann, et al.
Pageof 6